Compugen Ltd. (NASDAQ:CGEN – Free Report) – Equities researchers at HC Wainwright upped their FY2026 earnings per share estimates for shares of Compugen in a research report issued on Tuesday, August 4th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will earn ($0.35) per share for the year, up from their prior estimate of ($0.38). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen’s Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.41) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at ($0.44) EPS and FY2030 earnings at ($0.29) EPS.
Compugen (NASDAQ:CGEN – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $2.60 million during the quarter, compared to the consensus estimate of $1.28 million. Compugen had a return on equity of 42.57% and a net margin of 47.56%.During the same period last year, the company earned ($0.08) EPS.
View Our Latest Report on CGEN
Compugen Price Performance
NASDAQ CGEN opened at $2.28 on Thursday. The stock has a market capitalization of $215.58 million, a P/E ratio of 6.00 and a beta of 2.77. The firm’s 50-day moving average is $2.24 and its two-hundred day moving average is $2.27. Compugen has a 12 month low of $1.29 and a 12 month high of $3.23.
Hedge Funds Weigh In On Compugen
A number of hedge funds and other institutional investors have recently bought and sold shares of CGEN. Bank Hapoalim BM acquired a new position in Compugen in the 4th quarter valued at about $37,000. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Compugen during the fourth quarter worth about $38,000. Calamos Advisors LLC purchased a new position in shares of Compugen in the first quarter valued at approximately $63,000. Franklin Resources Inc. purchased a new position in shares of Compugen in the second quarter valued at approximately $56,000. Finally, Hillsdale Investment Management Inc. acquired a new position in shares of Compugen in the first quarter valued at approximately $68,000. 12.22% of the stock is currently owned by hedge funds and other institutional investors.
About Compugen
Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.
Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.
Featured Stories
- Five stocks we like better than Compugen
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.
